Etoricoxib

Etoricoxib

Warfarin - For patients who are stable on long-term warfarin therapy, the international normalized ratio (INR) of prothrombin time increases by about 13% when using 120 mg of Ankangxin daily. For patients receiving warfarin or similar drugs, INR values should be monitored when starting treatment with Ankangxin or changing treatment regimens, especially in the first few days. Rifampicin - Rifampicin is a strong inducer of liver metabolism. The co-administration of Ankangxin with it can reduce the plasma area under the curve (AUC) of Ankangxin by 65%. When Ankangxin is used with rifampicin, its interaction should be considered. Methotrexate - Two studies have observed the use of Ankangxin 60, 90 or 120 mg once a day for 7 days in patients with rheumatoid arthritis who were taking methotrexate 7.5 mg to 20 mg once a week. Ankangxin had no effect on methotrexate plasma concentrations (measured by AUC) and renal clearance at 60 and 90 mg levels. In one study, Anconxin 120 mg had no effect on methotrexate plasma concentrations (measured by AUC) or renal clearance. In another study, Anconxin 120 mg increased methotrexate plasma concentrations by 28% (measured by AUC) and decreased methotrexate renal clearance by 13%. When Anconxin is used at a dose greater than 90 mg/day and combined with methotrexate, monitoring for methotrexate-related side effects should be considered. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II antagonists (AllAs) - There are reports that non-selective NSAIDs and cyclooxygenase-2 inhibitors can reduce the antihypertensive effect of ACE inhibitors and angiotensin II antagonists. When Anconxin is used concomitantly with ACE inhibitors or angiotensin II antagonists, their interactions should be considered. In some patients with renal impairment who are being treated with NSAIDs, including selective cyclooxygenase-2 inhibitors, the combined use of ACE inhibitors or angiotensin II antagonists may lead to further impairment of renal function. This reaction is usually reversible. Lithium salts - There are reports that non-selective nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors can increase the plasma levels of lithium salts. This interaction should be considered for patients taking Ankangxin and lithium salts at the same time. Aspirin - Ankangxin can be used simultaneously with low-dose aspirin to prevent cardiovascular events. However, when used in combination with low-dose aspirin, the incidence of gastrointestinal ulcers or other complications is increased compared to using Ankangxin alone. In a stable state, Ankangxin 120 mg once daily has no effect on the antiplatelet activity of low-dose aspirin (81 mg once daily) (Precautions). Oral contraceptives - Using 60 mg of Ankangxin and an oral contraceptive containing 35 micrograms of ethinyl estradiol (EE) and 0.5-1 mg of norethindrone for 21 days can increase the AUC0-24hr of EE at steady state by 37%; taking 120 mg of Ankangxin and the same oral contraceptive at the same time or 12 hours apart can increase the AUC0-24hr of EE at steady state by 50-60%; when choosing an appropriate oral contraceptive to take with Ankangxin, the increase in EE concentration should be taken into account. Increased EE concentrations can increase the incidence of oral contraceptive-related adverse events (such as venous thrombosis-embolic events in high-risk women). Hormone replacement therapy: Concomitant use of 120 mg of Ankangxin and conjugated estrogens (0.625 mg of Premarin for 28 days) can increase the mean steady-state AUC0-24hr of unconjugated estrogen, equilin and 17-β-estradiol by 41%, 76% and 22%, respectively. The combined use of Ankangxin at the recommended long-term dose (60 mg and 90 mg) has not been studied. The effect of 120 mg of Ankangxin on the AUC0-24hr of these hormones is similar to that of Premarin alone and the dose is increased from 0.625 to 1 .5 mg is less than half of the latter. The clinical significance of these increases is unclear, and the use of higher doses of Premarin with Anconxin has not been studied. When choosing postmenopausal hormone replacement therapy for co-administration with Anconxin, the increase in estrogen concentrations should be taken into account. Others--In drug interaction studies, Anconxin did not have a clinically significant effect on the pharmacokinetics of prednisone/prednisolone or digoxin. Antacids and ketoconazole (a strong CYP3A4 inhibitor) did not have a clinically significant effect on the pharmacokinetics of Anconxin.

Etoricoxib.

1. Warfarin: For patients who have been treated with long-term warfarin and are stable, the international normalized ratio (INR) of prothrombin time increases by approximately 13% when this product is used 120 mg daily. For patients receiving warfarin or similar drugs, INR values should be monitored when starting treatment with this product or changing treatment regimens, especially in the initial few days. 2. Rifampicin: Rifampicin is a strong inducer of liver metabolism. The combination of this product with it can reduce the plasma area under the curve (AUC) of this product by 65%. When this product is used in combination with rifampicin, their interaction should be considered. 3. Methotrexate: Two studies have observed the situation in which patients with rheumatoid arthritis who were taking methotrexate 7.5 mg to 20 mg once a week received this product 60, 90 or 120 mg once a day for 7 consecutive days. This product was effective at 60 and

The main ingredient is etoricoxib.

1. Warfarin - For patients who are stable on long-term warfarin treatment, the international normalized ratio (INR) of prothrombin time increases by about 13% when this product is used at 120 mg daily. For patients who are treated with warfarin or similar drugs, the INR value should be monitored when starting treatment with this product or changing the treatment regimen, especially in the first few days. 2. Rifampicin - Rifampicin is a strong inducer of liver metabolism. The combination of this product with it can reduce the plasma area under the curve (AUC) of this product by 65%. When this product is used in combination with rifampicin, its interaction should be considered. 3. Methotrexate - Two studies have observed the situation of rheumatoid arthritis patients who were treated with methotrexate 7.5 mg to 20 mg once a week receiving this product 60, 90 or 120 mg once a day for 7 consecutive days. This product had no effect on the plasma concentration of methotrexate (determining AUC) and renal clearance at the 60 and 90 mg levels. In one of the studies, 120 mg of this product had no effect on the plasma concentration of methotrexate (determining AUC) or renal clearance. In another study, 120 mg of this product increased the plasma concentration of methotrexate by 28% (determined by AUC) and reduced the renal clearance of methotrexate by 13%. When this product is used at a dose greater than 90 mg/day and combined with methotrexate, monitoring for methotrexate-related toxic reactions should be considered. 4. Diuretics, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II antagonists (AIIAs) - There are reports that nonsteroidal anti-inflammatory drugs including cyclooxygenase-2 selective inhibitors can reduce the antihypertensive effect of diuretics, angiotensin-converting enzyme inhibitors and angiotensin II antagonists. When this product is used simultaneously with these products, their interactions should be considered. 5. For some patients with renal insufficiency who are being treated with nonsteroidal anti-inflammatory drugs including selective cyclooxygenase-2 inhibitors (e.g., elderly patients or patients with hypolytic disease, including those who are receiving diuretic therapy), the combined use of angiotensin-converting enzyme inhibitors or angiotensin II antagonists may cause further damage to renal function, including possible acute renal failure; but these effects are usually reversible. Therefore, combined use should be cautious, especially in elderly patients. 6. Lithium salts - There are reports that non-selective nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors can increase the plasma level of lithium salts. This interaction should be considered for patients taking this product and lithium salts at the same time. 7. Aspirin - This product can be used simultaneously with low-dose aspirin to prevent cardiovascular events. However, when used in combination with low-dose aspirin, the incidence of gastrointestinal ulcers or other complications is increased compared to using this product alone. In a stable state, 120 mg of this product once a day has no effect on the antiplatelet activity of low-dose aspirin (81 mg once a day) (see Precautions). 8. Oral contraceptives - The simultaneous use of 60 mg of this product and an oral contraceptive containing 35 micrograms of ethinyl estradiol (EE) and 0.5 to 1 mg of norethindrone for 21 consecutive days can increase the AUC0-24hr of EE at a steady state by 37%; 120 mg of this product and the same oral contraceptive are taken at the same time or 12 hours apart. It can increase the steady-state AUC0-24hr of EE by 50%-60%. When choosing an appropriate oral contraceptive to be taken with this product, the increase in EE concentration should be taken into account. The increase in EE concentration increases the incidence of oral contraceptive-related adverse events (such as the risk of venous thromboembolism in women). 9. Hormone replacement therapy: The simultaneous use of 120 mg of Fengpin and hormone replacement therapy containing conjugated estrogens (0.625 mg of Premarin) for 28 consecutive days can increase the average steady-state AUC0-24hr of unconjugated estrone, equilin and 17-beta;-estradiol by 41%, 76% and 22%, respectively. The combination of this product with the recommended dose (60 mg and 90 mg) for long-term use has not been studied. The effect of 120 mg of this product on the AUC0-24hr of these estrogens is less than half of that of Premarin alone and the dose is increased from 0.625 to 1.25 mg. The clinical significance of these elevated levels is unclear, and the use of higher doses of Premarin in combination with this product has not been studied. When choosing postmenopausal hormone replacement therapy and taking this product simultaneously, the elevated estrogen concentrations should be considered. 10. Others - In drug interaction studies, this product did not produce a clinically significant effect on the pharmacokinetics of prednisone/prednisolone or digoxin. 11. Antacids and ketoconazole (a strong CYP3A4 inhibitor) did not produce a clinically significant effect on the pharmacokinetics of this product.